Solid-state characterization and dissolution properties of Fluvastatin sodium salt hydrates

References

• Levy RI, Troendle AJ, Fattu JM. A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation 1993;87:III45–III53.
   PubMed Web of Science ®Google Scholar
• Blum CB. Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Am J Cardiol 1994;73:3D–11D.
   PubMed Web of Science ®Google Scholar
• Othawa M, Uchiyama N, Saito Y, Suzuki A, Tanno C. Phase I study of MK- 733, an inhibitor of HMG-COA reductase II, Pharmacokinetics of MK-733 in healthy subjects after single and multiple oral administration. Rinsh Iyaku 1989;5:1123–1140.
   Google Scholar
• Food and Drug Administration. <http://www.fda.gov/CDER/ >. Accessed on 22 August 2011.
   Google Scholar
• Trung TQ, Dung PT, Hoan NN, Kim DJ, Lee JH, Kim KH. Chiral separation of fluvastatin enantiomers by capillary electrophoresis. Arch Pharm Res 2008;31:1066–1072.
   PubMed Web of Science ®Google Scholar
• Li JJ (2009). Triumph of the heart: the story of statins. New York, NY: Oxford University Press, 88.
   Google Scholar
• Zacharia JT, Tanaka T, Hayashi M. Facile and highly enantioselective synthesis of (+)- and (-)-Fluvastatin and their analogues. J Org Chem 2010;75:7514–7518.
   Google Scholar
• Sorrentia M, Catenaccia L, Brunib G, Luppic B, Biguccic F, Bettinetti G. Solid-state characterization of tacrine hydrochloride. J Pharm Biom Anal 2012; 63:53–61.
   PubMed Web of Science ®Google Scholar
• Papageorgiou GZ, Papadimitriou S, Karavas E, Georgarakis E, Docoslis A, Bikiaris D. Improvement in chemical and physical stability of fluvastatin drug through hydrogen bonding interactions with different polymer matrices. Curr Drug Deliv 2009;6:101–112.
   PubMedGoogle Scholar
• Panda HS, Srivastava R, Bahadur D. In-vitro release kinetics and stability of anticardiovascular drugs-intercalated layered double hydroxide nanohybrids. J Phys Chem B 2009;113:15090–15100.
   PubMed Web of Science ®Google Scholar
• Horwath K. Polymorphic compounds. 2000. Patent application number: US 6124340. <http://ip.com/patent/US6124340>. Accessed on 22 August 2011.
   Google Scholar
• Van der Schaaf PA, Marcolli C, Szelagiewicz M, Burkhard A, Wolleb H, Wolleb A. Crystalline forms. Patent application number: US 0032666A1. <http://ip.com/patapp/US20030032666>. Accessed on 22 August 2011.
   Google Scholar
• Van Der Schaaf PA, Wolleb H, Wolleb A, Marcolli C, Szelagiewicz M, Burkhard A, Freiermuth B. Crystalline forms of fluvastatin sodium. Patent application number: US 6858643B2, 2005. <http://ip.com/patent/US6858643>. Accessed on 22 August 2011.
   Google Scholar
• Van Der Schaaf PA, Blatter F. Szelagiewicz M. Crystalline form of fluvastatin sodium. 2006. Patent application number: US 02041167A1. <http://ip.com/patapp/US20060241167>. Accessed on 22 August 2011.
   Google Scholar
• Huang L. Anhydrous amorphous form of fluvastatin. Patent application number: US 7241800, 2007. <http://www.patentgenius.com/patent/7241800.html>. Accessed on 22 August 2011.
   Google Scholar
• Chavhan B, Awasthi AK, Aggarwal R, Beena RS, Paul S, Thaper RK, Dubey SK. . Novel polymorphic forms of fluvastatin sodium and process for preparing the same. 2008. Patent application number: 20080207919. <http://www.faqs.org/patents/app/20080207919>. Accessed on 22 August 2011.
   Google Scholar
• Lifshitz-Liron HR, Koltai NT, Aronhime RJ, Perlman KSN, Avhar-Maydan GS. Fluvastatin crystal forms, processes for preparing them, compositions containing them and methods to using them. 2009. Patent application number: US 0209611A1. <http://ip.com/patapp/US20090209611>. Accessed on 22 August 2011.
   Google Scholar
• USP 34, The United Stated Pharmacopeia. Rockville, MD: United States Pharmacopoeia Convention Inc. 2011.
   Google Scholar
• Zakeri-Milani P, Barzegar-Jalali M, Azimi M, Valizadeh H. Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. Eur J Pharm Biopharm 2009;73:102–106.
   PubMed Web of Science ®Google Scholar
• Mirmehrabi M, Rohani S. An approach to solvent screening for crystallization of polymorphic pharmaceuticals and fine chemicals. J Pharm Sci 2005;94:1560–1576.
   PubMed Web of Science ®Google Scholar
• Gomes FP, García PL, Alves JMP, Singh, AK, Kedor-Hackmann ERM, Santoro MIRM. Development and validation of stability-indicating HPLC methods for quantitative determination of pravastatin, fluvastatin, atorvastatin and rosuvastatin in pharmaceutics. Anal Lett 2009;42:1784–1804.
   Web of Science ®Google Scholar
• Yu LX, Carlin AS, Amidon GL, Hussain AS. Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. Int J Pharm 2004;270:221–227.
   PubMed Web of Science ®Google Scholar
• Yu LX, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res 2002;19:921–925.
   PubMed Web of Science ®Google Scholar
• Kasim NA, Whitehouse M, Ramachandran C, Bermejo M, Lennernäs H, Hussain AS et al. Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm 2004;1:85–96.
   PubMed Web of Science ®Google Scholar
• Moffat AC, Osselton MD, Widdop B. Clarke’s analysis of drugs and poisons: in pharmaceuticals, body fluids and postmortem material. 3rd ed. London: Pharmaceutical Press, 2004.
   Google Scholar
• Cermola F, Dellagreca M, Iesce MR, Montanaro S, Previtera L, Temussi F, Brigante M. Irradiations of fluvastatin in water structure elucidation of photoproducts. J Photochem Photobiol A 2007;189:264–271.
   Google Scholar
• Harris RK. NMR studies of organic polymorphs and solvates. Analyst 2006;131:351–373.
   PubMed Web of Science ®Google Scholar
• Carss, S, Harris RK, Fletton RA. Carbon-13 NMR investigations of three fluorinated steroids. Magn Res Chem 1995;33:501–505.
   Web of Science ®Google Scholar
• Park JS, Kang HW, Park SJ, Kim CK. Use of CP/MAS solid-state NMR for the characterization of solvate molecules within estradiol crystal forms. Eur J Pharm Biopharm 2005;60:407–412.
   PubMed Web of Science ®Google Scholar
• Bott RF, Oliveira WP. Storage conditions for stability testing of pharmaceuticals in hot and humid regions. Drug Dev Ind Pharm 2007;33:393–401.
   PubMed Web of Science ®Google Scholar
• Infantes L, Chisholm J, Motherwell S. Extended motifs from water and chemical functional groups in organic molecular crystals. Cryst Eng Comm 2003; 5:480–486.
   Web of Science ®Google Scholar
• Byrn SR, Pfeiffer RR, Stowell JG. Solid state chemistry of drugs. 2nd ed. Indiana: West Lafayette, 1999.
   Google Scholar